Shareholder Alert: Ademi LLP investigates whether ImmunoGen, Inc. has obtained a Fair Price in its transaction with AbbViePRNewsWire • 11/30/23
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash DealInvestors Business Daily • 11/30/23
ImmunoGen (IMGN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/30/23
These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.Market Watch • 11/30/23
IMGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to ShareholdersBusiness Wire • 11/30/23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor PortfolioPRNewsWire • 11/30/23
Biotech Leader ImmunoGen Eyes Early Buy Point Amid Path To ProfitabilityInvestors Business Daily • 11/27/23
Wall Street Analysts Believe ImmunoGen (IMGN) Could Rally 52.99%: Here's is How to TradeZacks Investment Research • 11/22/23
ImmunoGen (IMGN) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 11/15/23
Wall Street Analysts See a 40.58% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?Zacks Investment Research • 11/06/23